Francois Dionne1, Folefac Aminkeng2,3,4, Amit P Bhavsar5, Gabriella Groeneweg2,3,6, Anne Smith2,3,6, Henk Visscher2,4, Shahrad Rod Rassekh2,7, Colin Ross2,8, Bruce Carleton2,3,6. 1. Centre for Clinical Epidemiology and Evaluation, Vancouver, British Columbia, Canada. 2. BC Children's Hospital Research Institute (formerly known as the Child and Family Research Institute), Vancouver, British Columbia, Canada. 3. Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 4. Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 5. Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada. 6. Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada. 7. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. 8. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: Anthracyclines are a class of highly effective chemotherapeutic drugs commonly used to treat cancer patients. Anthracyclines, however, are associated with the development of serious adverse reactions, including anthracycline-induced cardiotoxicity (ACT). It is not possible, within current practice, to accurately individualize treatment to minimize risk. PROCEDURE: Recently, genetic variants have been associated with the risk of ACT in children. Building on these findings and the related genetic test, a predictive model was developed which classifies pediatric patients by their risk of developing ACT. We assessed the value of this ACT-predictive risk classification in addressing ACT. RESULTS: With current care, the estimated average lifetime cost of ACT is $8,667 per anthracycline-treated patient and approximately 7% of patients are expected to die from ACT. The projected impact of the information from the new predictive model is a 17% reduction in the risk of mortality from ACT and savings of about 6%: lives saved and lower costs. CONCLUSION: The newly identified genetic variants associated with the risk of ACT provide information that allows a more reliable prediction of the risk of ACT for a given patient and can be obtained at a very moderate cost, which is expected to lead to meaningful progress in reducing harm and costs associated with ACT.
BACKGROUND:Anthracyclines are a class of highly effective chemotherapeutic drugs commonly used to treat cancerpatients. Anthracyclines, however, are associated with the development of serious adverse reactions, including anthracycline-induced cardiotoxicity (ACT). It is not possible, within current practice, to accurately individualize treatment to minimize risk. PROCEDURE: Recently, genetic variants have been associated with the risk of ACT in children. Building on these findings and the related genetic test, a predictive model was developed which classifies pediatric patients by their risk of developing ACT. We assessed the value of this ACT-predictive risk classification in addressing ACT. RESULTS: With current care, the estimated average lifetime cost of ACT is $8,667 per anthracycline-treated patient and approximately 7% of patients are expected to die from ACT. The projected impact of the information from the new predictive model is a 17% reduction in the risk of mortality from ACT and savings of about 6%: lives saved and lower costs. CONCLUSION: The newly identified genetic variants associated with the risk of ACT provide information that allows a more reliable prediction of the risk of ACT for a given patient and can be obtained at a very moderate cost, which is expected to lead to meaningful progress in reducing harm and costs associated with ACT.
Authors: Catrina M Loucks; Gabriella Groeneweg; Carl Roy; David K Lee; Michael J Rieder; Denis Lebel; Shinya Ito; Colin J Ross; Bruce C Carleton Journal: Can Fam Physician Date: 2020-04 Impact factor: 3.275
Authors: Catrina M Loucks; Gabriella Groeneweg; Carl Roy; David K Lee; Michael J Rieder; Denis Lebel; Shinya Ito; Colin J Ross; Bruce C Carleton Journal: Can Fam Physician Date: 2020-04 Impact factor: 3.275
Authors: Oliver Zolk; Annika von dem Knesebeck; Norbert Graf; Thorsten Simon; Barbara Hero; Hashim Abdul-Khaliq; Mohamed Abd El Rahman; Claudia Spix; Benjamin Mayer; Susanne Elsner; Judith Gebauer; Thorsten Langer Journal: JMIR Res Protoc Date: 2022-02-17